GURU.Markets stock price, segment price, and overall market index valuation
The company's share price CERo Therapeutics
The value of CERo Therapeutics, a cell therapy company, is determined by the progress of its research. The potential share price will depend on the results of clinical trials of its innovative cancer treatment platform.
Share prices of companies in the market segment - Oncology cell gene therapy
CERo Therapeutics is an oncology company developing a novel cell therapy platform (CER-T) aimed at killing cancer cells. We've categorized it under "Oncology: Cell Therapy." The chart below shows how the market is evaluating innovative approaches in immuno-oncology.
Broad Market Index - GURU.Markets
CERo Therapeutics is an oncology company developing a new cell therapy platform for cancer treatment. Its innovations have earned it a spot in the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
CERO - Daily change in the company's share price CERo Therapeutics
For CERo Therapeutics Holdings, Inc., an immuno-oncology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical metric for assessing risk.
Daily change in the price of a set of shares in a market segment - Oncology cell gene therapy
CERo Therapeutics develops innovative cell therapies for cancer treatment. Immuno-oncology is a cutting-edge and highly volatile segment of biotechnology. The chart below shows average daily fluctuations in this field, allowing you to assess the risks and potential of CERO stock.
Daily change in the price of a broad market stock, index - GURU.Markets
CERo Therapeutics is a biotech company working on cell therapy. Its shares are a bet on scientific breakthroughs. Their extreme volatility, driven by research data, is part of the dynamics of the innovation sector, which impacts the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization CERo Therapeutics
CERo Therapeutics' year-over-year performance is a story of developing a new generation of cell therapy. Its 12-month market cap is entirely dependent on early clinical trial data. The success of its platform, which "teaches" macrophages to attack cancer cells, could be a breakthrough in the treatment of solid tumors.
Annual dynamics of market capitalization of the market segment - Oncology cell gene therapy
As an early-stage biotech company, CERo is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its cell therapy. Its stock price will reflect investors' speculative belief in the potential of its developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
CERo Therapeutics, a biopharmaceutical company developing a new class of cell therapies for cancer, is betting on the next breakthrough in oncology. Its annual market capitalization growth is almost entirely dependent on the results of preclinical and early clinical trials, which is typical for venture-backed biotechs.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization CERo Therapeutics
CERo Therapeutics is an immuno-oncology company. Its monthly performance is typical for an early-stage biotech: it depends entirely on progress in its scientific developments. News about preclinical studies of its platform are the main catalysts.
Monthly dynamics of market capitalization of the market segment - Oncology cell gene therapy
CERo Therapeutics is developing a new class of engineered T cells for cancer treatment. Their technology is designed to engulf and destroy cancer cells. The company's success depends entirely on the results of clinical trials. The cell and gene therapy sector's chart reflects overall investor interest in this revolutionary, yet risky, field of medicine.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
CERo Therapeutics develops innovative cell therapy for cancer treatment. This is a cutting-edge, yet risky, area of biotechnology. The company's shares move not in response to the market, but in anticipation of laboratory breakthroughs. Any news about clinical trials can cause sharp fluctuations, completely ignoring overall economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization CERo Therapeutics
CERo Therapeutics is developing an innovative cell therapy that "marks" cancer cells for destruction by the immune system. Its weekly stock price reflects investor faith in this cutting-edge scientific approach. News about preclinical studies is causing sharp fluctuations.
Weekly dynamics of market capitalization of the market segment - Oncology cell gene therapy
CERo Therapeutics is developing a new cell therapy platform for cancer treatment. This is a cutting-edge field with high potential and risks. The company's weekly stock price performance will likely be driven by research news. The chart will show how its path diverges from the overall biotech trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
CERo Therapeutics is a company developing cutting-edge cell therapy for cancer. Its stock is a classic biotech whose performance depends on news about trials. The chart clearly demonstrates this disconnect from the broader market and its macroeconomic drivers.
Market capitalization of the company, segment and market as a whole
CERO - Market capitalization of the company CERo Therapeutics
CERo Therapeutics' market capitalization chart reflects investors' bets on its new cell therapy platform. Its dynamics reflect the market's belief that its technology can create safer and more effective immune cells to fight cancer. Its value reflects the company's scientific potential, which is still in the very early, preclinical stage.
CERO - Share of the company's market capitalization CERo Therapeutics within the market segment - Oncology cell gene therapy
CERo Therapeutics is developing a new class of engineered T cells for cancer treatment. Its stake in the biotech sector is negligible, but it is based on an innovative idea. The company's capitalization is a bet on its CER-T platform, which aims to improve the safety and efficacy of cell therapy.
Market capitalization of the market segment - Oncology cell gene therapy
Here's a chart reflecting the combined weight of the entire biotech sector specializing in cell and gene therapy. For CERo Therapeutics, with its innovative platform, this line represents the future of oncology. The rising chart represents an influx of capital into technologies that promise to "teach" the immune system to recognize and destroy cancer cells.
Market capitalization of all companies included in a broad market index - GURU.Markets
CERo Therapeutics is developing a new type of cell therapy for cancer. Its market capitalization reflects its innovative scientific platform. This represents a tiny fraction of the overall market, representing another bold approach in immuno-oncology.
Book value capitalization of the company, segment and market as a whole
CERO - Book value capitalization of the company CERo Therapeutics
CERo Therapeutics is developing a new generation of cell therapy for cancer. Its book value is its scientific and financial capital. It consists of cash for R&D and the value of its unique technological platform. How has this capital changed? The chart below shows this history.
CERO - Share of the company's book capitalization CERo Therapeutics within the market segment - Oncology cell gene therapy
CERo Therapeutics is a cell therapy company. Its innovative platform requires a sophisticated infrastructure: in-house R&D labs to develop its own T-cell enhancers (CER-T). The chart shows the company's share of the physical infrastructure required to create next-generation immunotherapy.
Market segment balance sheet capitalization - Oncology cell gene therapy
CERo Therapeutics is an oncology company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. CERo focuses on drug development, and its capital lies in its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
CERo Therapeutics' assets are not factories, but a scientific platform for developing a new type of cell therapy (CER-T), which trains macrophages to attack cancer tumors. The book value reflects the laboratory base for this cutting-edge immuno-oncology research.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - CERo Therapeutics
CERo Therapeutics is an oncology company developing a new type of cell therapy. Its market value is derived from its innovative scientific platform. Investors are betting on its potential to create a safer and more effective cancer treatment.
Market to book capitalization ratio in a market segment - Oncology cell gene therapy
CERo Therapeutics is a biotech company developing a new type of cell therapy for cancer. Its high valuation on this chart reflects investors' faith in its innovative scientific platform, which could offer new treatment options for cancer patients.
Market to book capitalization ratio for the market as a whole
CERo Therapeutics is developing a new generation of cell therapy for cancer. The company's market value reflects investors' faith in its scientific platform. This chart shows the significant premium the market is willing to pay for cutting-edge and potentially revolutionary approaches in oncology, even if they are in the early stages.
Debts of the company, segment and market as a whole
CERO - Company debts CERo Therapeutics
CERo Therapeutics, a preclinical biotech developing a novel cell therapy platform, relies entirely on venture capital. All funds are directed toward proof-of-concept research. This timeline reflects the initial, riskiest phase of developing a breakthrough technology.
Market segment debts - Oncology cell gene therapy
CERo Therapeutics is a preclinical biotech company developing a new type of cell therapy for cancer. This chart depicts the startup's financial model, which is raising venture capital to fund its early, yet potentially breakthrough, research in the field of immuno-oncology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio CERo Therapeutics
CERo Therapeutics develops innovative cell therapies for cancer. The development and clinical trials of such complex "living drugs" are extremely expensive and time-consuming. This chart illustrates how heavily the company relies on debt to finance its cutting-edge, yet high-risk, research.
Market segment debt to market segment book capitalization - Oncology cell gene therapy
CERo Therapeutics is developing a new type of cell therapy (CAR-T) for cancer treatment. This is one of the most advanced and expensive areas in medicine. This chart shows how the company finances its unique research. It relates its debt structure to the overall financial picture in the capital-intensive biotech sector.
Debt to book value of all companies in the market
CERo Therapeutics is developing a new type of cell therapy for cancer. This is one of the most advanced and capital-intensive areas of biotech. How heavily will the company rely on debt financing for its breakthrough research? This chart of total debt in the economy helps assess the scale of future financial risks.
P/E of the company, segment and market as a whole
P/E - CERo Therapeutics
CERo Therapeutics is a biopharmaceutical company developing a novel cell therapy platform for cancer treatment. This chart reflects speculative investor interest in its innovative approach. The valuation is heavily dependent on the results of preclinical and early clinical trials.
P/E of the market segment - Oncology cell gene therapy
CERo Therapeutics is a biotech company developing a novel cancer cell therapy platform that "trains" macrophages (a type of immune cell) to attack tumor cells. This chart illustrates the average valuation in the cell and gene therapy sector, where investors are betting on revolutionary approaches to cancer treatment.
P/E of the market as a whole
CERo Therapeutics is a biopharmaceutical company developing a novel cell therapy platform that enables the creation of engineered macrophages to fight cancer. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether CERO's high valuation is based on faith in its innovative scientific approach or is driven by overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company CERo Therapeutics
CERo Therapeutics is developing a new class of engineered T cells for cancer immunotherapy. Their technology aims to improve the efficacy and safety of cell therapy. This chart demonstrates the level of investor confidence in the company's scientific approach and its ability to create breakthrough treatments, which shapes future revenue expectations.
%20P%2FE%20CERo%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-CERo-Therapeutics&v=1772513903878 "Chart of the company's future (projected) P/E CERo Therapeutics")
Future (projected) P/E of the market segment - Oncology cell gene therapy
CERo Therapeutics is developing a new type of cell therapy for cancer that utilizes both innate and adaptive immunity to destroy tumors. The chart shows average profitability expectations for the sector, helping to understand the level of investor confidence in this innovative approach and its potential for creating breakthrough drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-cell-gene-therapy&v=1772513903921 "Future (projected) P/E graph of the market segment - Oncology cell gene therapy")
Future (projected) P/E of the market as a whole
CERo Therapeutics is developing a new generation of cell therapy for cancer. The technology aims to "teach" immune cells to attack tumors. This biotech risk appetite chart reflects investors' willingness to fund cutting-edge, yet highly complex and expensive, cancer treatments.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513904084 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit CERo Therapeutics
CERo Therapeutics is a preclinical biotech company developing a novel cell therapy platform for cancer. Its financial performance is based solely on research expenses. This chart shows the earliest investments in a scientific concept that could one day become a new cancer treatment.
Profit of companies in the market segment - Oncology cell gene therapy
CERo Therapeutics is a biotech company developing a novel cancer cell therapy platform that "trains" macrophages (a type of immune cell) to attack tumors. This chart shows the overall profitability of the oncology cell therapy sector, one of the hottest and most competitive areas in modern biopharmaceuticals.
Overall market profit
CERo Therapeutics is developing a new generation of cell therapy for cancer treatment. The company is at the forefront of biomedical innovation. Its value and future are determined solely by scientific progress and clinical trial results, not by macroeconomic trends, as can be seen in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company CERo Therapeutics
CERo Therapeutics is developing a new class of engineered T cells for cancer treatment. Future profits depend entirely on the success of this cutting-edge technology in clinical trials. This chart reflects analysts' highly speculative expectations regarding the future of cellular immunotherapy and CERo's role in it.
%20profit%20of%20the%20company%20CERo%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-CERo-Therapeutics&v=1772513904440 "Graph of future (projected) profit of the company CERo Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology cell gene therapy
CERo Therapeutics is a biotech company developing a novel cell therapy platform for cancer treatment. Its CER-T technology aims to induce cancer cells to "eat" each other. This chart shows revenue projections for the cell and gene therapy sector, providing context for evaluating CERo's innovative approach to cancer treatment.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-cell-gene-therapy&v=1772513904498 "Graph of future (predicted) profits of companies in a market segment - Oncology cell gene therapy")
Future (predicted) profit of the market as a whole
CERo Therapeutics is a biotech company developing a new class of cell therapies for cancer treatment. Its survival and growth are entirely dependent on raising funding. This earnings expectations chart reflects the overall sentiment of investors and their willingness to invest in high-risk but potentially breakthrough scientific projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513904574 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - CERo Therapeutics
CERo Therapeutics is developing a new generation of cell therapy for cancer. Being in the preclinical stage, the company has no revenue. This chart reflects investors' faith in its scientific platform and its potential to create an effective and safe cancer treatment.
P/S market segment - Oncology cell gene therapy
CERo Therapeutics is developing a new generation of cell therapy for cancer treatment. Their technology aims to "train" immune cells, or macrophages, to recognize and destroy tumor cells, opening up new opportunities in immuno-oncology. This chart reflects the average revenue estimate for the sector, helping to assess the potential of this cutting-edge platform.
P/S of the market as a whole
CERo Therapeutics is a biotech company developing a new type of cell therapy for cancer that "marks" tumor cells for destruction by the immune system. This chart emphasizes that the valuation of such companies is based on the breakthrough potential of their scientific platform, not on current financial performance.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company CERo Therapeutics
CERo Therapeutics is a preclinical biopharmaceutical company developing a novel cell therapy platform for cancer treatment. For such an innovative company, valuing its future revenue is hypothetical, but crucial. It reflects investors' faith in the scientific potential of its technology and its long-term ability to develop effective anti-cancer drugs.
%20P%2FS%20CERo%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-CERo-Therapeutics&v=1772513904703 "The graph of the company's future (projected) P/S CERo Therapeutics")
Future (projected) P/S of the market segment - Oncology cell gene therapy
CERo Therapeutics is developing a new class of immunotherapeutic drugs—CER-T cells—that target cancer cells. This chart compares the company's estimated future sales with expectations for the biotech sector. It shows how investors view the potential of its innovative cell therapy to create safer and more effective cancer treatments.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-cell-gene-therapy&v=1772513904710 "Future (projected) P/S market segment graph - Oncology cell gene therapy")
Future (projected) P/S of the market as a whole
CERo Therapeutics is developing a new cell therapy platform for cancer treatment that uses engineered T cells to engulf and destroy tumor cells. The company's future depends on the success of this innovative technology. This chart of overall market expectations reflects investor confidence that cell therapy will revolutionize oncology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513904735 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales CERo Therapeutics
This chart reflects the financial activity of CERo Therapeutics, an early-stage biotech company developing a novel cell therapy platform for cancer treatment. There are no commercial sales revenues, and cash flows are derived from raising capital for preclinical and early clinical trials.
Sales of companies in the market segment - Oncology cell gene therapy
CERo Therapeutics is a biopharmaceutical company developing a novel cell therapy platform for cancer treatment. Being in the preclinical stage, it does not yet have revenue. Its valuation is based on the potential of its innovative technology, and future revenue depends on the successful clinical advancement of its developments.
Overall market sales
CERo Therapeutics is a preclinical biotechnology company developing a novel cell therapy platform for cancer treatment. Its prospects depend entirely on the success of its scientific research. This overall economic performance chart is completely irrelevant for a company whose value lies in its potential to make a breakthrough in oncology.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company CERo Therapeutics
CERo Therapeutics is a biotechnology company developing a novel cell therapy platform (CAR-T) for cancer treatment. Its technology aims to improve the efficacy and safety of treatment. Future revenue is dependent on the success of clinical trials. This chart reflects analyst expectations for the commercial potential of its innovative therapeutic platform.
%20sales%20of%20the%20company%20CERo%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-CERo-Therapeutics&v=1772513904831 "Schedule of future (projected) sales of the company CERo Therapeutics")
Future (projected) sales of companies in the market segment - Oncology cell gene therapy
CERo Therapeutics is developing a new generation of cell therapy for cancer. This chart shows the forecast for the oncology sector. Will a breakthrough in cell engineering drive growth for the entire immunotherapy market? This chart provides an overview of the industry's overall scientific and commercial potential.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-cell-gene-therapy&v=1772513904836 "Schedule of future (projected) sales of companies in the market segment - Oncology cell gene therapy")
Future (projected) sales of the market as a whole
CERo Therapeutics is a biotech company developing innovative cell therapies for cancer treatment. Its future depends solely on scientific progress and clinical trial results. The general economic cycles reflected in this chart bear no relation to the fundamental drivers and risks in this cutting-edge field of medicine.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513904846 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality CERo Therapeutics
CERo Therapeutics is an early-stage biotech company developing a novel cell therapy platform for cancer treatment. This chart reflects its financial performance at the preclinical stage. Profitability is a very distant goal, dependent entirely on the success of its innovative technology and its ability to attract significant funding for clinical trials.
Market segment marginality - Oncology cell gene therapy
CERo Therapeutics, Inc. is a preclinical biotechnology company developing a novel cell therapy platform for cancer. Its financial performance is entirely driven by research expenses. Profitability is a very long-term prospect, dependent on the successful advancement of its scientific concept through multiple development stages.
Market marginality as a whole
CERo Therapeutics is developing a new class of cell therapies for cancer treatment. The company is at the forefront of immuno-oncology, requiring significant investment in R&D. This total return chart reflects investors' risk appetite, which determines the availability of capital for such breakthrough, yet capital-intensive, projects.
Employees in the company, segment and market as a whole
Number of employees in the company CERo Therapeutics
CERo Therapeutics is an early-stage biotech company developing a novel platform for cancer cell therapy. Its very small team consists of the founders and leading scientists. This timeline is typical for a cutting-edge technology startup: the team will only grow after proof of concept and significant funding.
Share of the company's employees CERo Therapeutics within the market segment - Oncology cell gene therapy
CERo Therapeutics is a biotechnology company developing a new type of cell therapy for cancer treatment. Its team consists of highly specialized scientists in immunology and genetic engineering. This graph shows the company's market share, reflecting its scientific potential in one of the most advanced fields of modern oncology.
Number of employees in the market segment - Oncology cell gene therapy
CERo Therapeutics is developing a new cell therapy platform for cancer treatment. Their "CER-T" technology is designed to train immune cells (macrophages) to recognize and destroy tumors. The graph illustrates the current state of the cell therapy sector. This approach represents a new and promising direction in the fight against cancer.
Number of employees in the market as a whole
CERo Therapeutics is a biotech company developing a new class of cell therapies for cancer treatment. It's at the cutting edge of science. Its staff growth isn't a reflection of economics, but a direct consequence of research progress. Given the overall dynamics in this chart, CERo represents the venture sector, where jobs are being created to foster future breakthroughs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company CERo Therapeutics (CERO)
CERo Therapeutics is a biotech company developing next-generation cell therapy (CER-T) for cancer treatment. It's pure high-tech in medicine. This chart shows the enormous speculative value the market is placing on their platform. It reflects the market capitalization per scientist, a bet on a scientific breakthrough.
%20of%20the%20company%20CERo%20Therapeutics%20(CERO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-CERo-Therapeutics-CERO&v=1772513905045 "Chart of market capitalization per employee (in thousands of dollars) of the company CERo Therapeutics (CERO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
CERo Therapeutics (CERO) is developing a new cell therapy platform for cancer treatment. In advanced oncology, the market capitalization per employee is a measure of the scientific platform. A very high figure could indicate that their CER-T technology is capable of overcoming the limitations of existing CAR-T therapies, representing a significant advance in the fight against cancer.
%20by%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-cell-gene-therapy&v=1772513905062 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology cell gene therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
CERo Therapeutics is developing a new platform for cell-based cancer therapy. The company's value lies in its innovative scientific concept. The chart shows a high valuation per employee, as the market sees potential for safer and more effective cancer treatments than existing CAR-T therapies.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513905103 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company CERo Therapeutics (CERO)
CERo Therapeutics is a preclinical biotech company developing a novel cell therapy platform for cancer treatment. This chart shows the net loss per employee. It reflects the company's team of scientists, whose work is 100% investor-funded R&D to create the technology of the future.
%20Chart%20CERo%20Therapeutics%20(CERO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-CERo-Therapeutics-CERO&v=1772513905137 "Company Profit Per Employee (in thousands of dollars) Chart CERo Therapeutics (CERO)")
Profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
CERo Therapeutics is a biotech company developing a new class of cell therapies for cancer treatment. In advanced oncology, efficiency per employee reflects the potential of a scientific platform. This graph shows the financial return per team, allowing one to evaluate the company's progress in developing breakthrough treatments compared to other players.
%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-cell-gene-therapy&v=1772513905150 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy")
Profit per employee (in thousands of dollars) for the market as a whole
CERo Therapeutics is a biotech company developing a novel cell therapy platform (CE-CAR) for cancer treatment. They are at the forefront of oncology. Their business is pure science and R&D. This chart, showing average market performance, helps clarify the contrast with biotech, where teams of scientists burn through capital in hopes of a breakthrough.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513905158 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee CERo Therapeutics (CERO)
CERo Therapeutics is a biotech company developing a new class of cell therapy for cancer treatment. There is no revenue per employee during the research phase. The graph represents a future estimate: a successful therapeutic platform could generate billions, making this figure astronomical.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-CERo-Therapeutics-CERO&v=1772513905178 "Sales chart per company employee CERo Therapeutics (CERO)")
Sales per employee in the market segment - Oncology cell gene therapy
CERo Therapeutics is an early-stage (preclinical) biotech developing a novel cell therapy platform (CAR-T) for the treatment of oncology. They have no commercial revenue. This chart, showing the average revenue in the sector, serves as a barometer of CERO's R&D staff burn rate.
Sales per employee for the market as a whole
CERo Therapeutics is a preclinical biotech company developing a new type of cell therapy (CER-T) for the treatment of cancer. Currently, the company has no commercial revenue. This chart reflects their status as an R&D startup investing in laboratory research.
Short shares by company, segment and market as a whole
Shares shorted by company CERo Therapeutics (CERO)
CERo Therapeutics (CERO) is an early-stage biotech developing cell therapies for cancer. This chart shows the volume of bearish bets. "Shorts" in preclinical biotechs are bets that their technology will fail to prove safe and effective when it moves to human trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-CERo-Therapeutics-CERO&v=1772513905270 "Short Shares Chart for the Company CERo Therapeutics (CERO)")
Shares shorted by market segment - Oncology cell gene therapy
CERo Therapeutics (CERO) is a biotech company developing a novel cell therapy platform (CAR-T) for the treatment of cancer. This chart aggregates short positions across the entire oncology biotech sector. It reflects general investor skepticism regarding the risks of clinical trials and the complexities of cell therapy.
Shares shorted by the overall market
CERo Therapeutics is an early-stage biotech company (cell therapy). This chart illustrates the overall market pessimism. For investors, this is a risky scientific project. When fear dominates, the market does not trust such companies, fearing they will burn through all their cash on R&D and fail to attract new funding rounds.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator CERo Therapeutics (CERO)
CERo Therapeutics is developing cell therapy for cancer. This is a highly speculative and competitive field of biotech. This chart measures the feverish anticipation. It shows how investor sentiment can become overheated on early, encouraging data, followed by a prolonged cooldown.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-CERo-Therapeutics-CERO&v=1772513905327 "RSI 14 indicator chart for the company's stock CERo Therapeutics (CERO)")
RSI 14 Market Segment - Oncology cell gene therapy
CERo Therapeutics (CERO) is a biotech company developing a new type of cell therapy (TCR). They "train" immune cells to attack cancer. This chart tracks the collective sentiment in the Cell/Gene Oncotherapy sector. It shows when the entire industry is overheated by hype surrounding breakthroughs or oversold by setbacks.
RSI 14 for the overall market
For CERo Therapeutics, a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the cash spigot is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CERO (CERo Therapeutics)
CERo Therapeutics is a preclinical-stage biotech developing a next-generation cell therapy (CER-T) for cancer treatment. This chart shows the highly speculative average price target from analysts, which is based entirely on their belief in this early-stage R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CERO-CERo-Therapeutics&v=1772513905380 "A chart showing analyst consensus forecasts for the expected stock price. CERO (CERo Therapeutics)")
The difference between the consensus estimate and the actual stock price CERO (CERo Therapeutics)
CERo Therapeutics is a biotech company developing a next-generation cell therapy (CER-T) for cancer treatment. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and the forecast, reflecting their "venture capital" valuation of this early-stage R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CERO-CERo-Therapeutics&v=1772513905399 "A chart showing the difference between the consensus forecast and the actual stock price. CERO (CERo Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology cell gene therapy
CERo Therapeutics (CERO) is a biotech company developing a cell therapy (CER-T) for the treatment of blood cancers, which is expected to be safer than CAR-T. This chart shows general expectations for the cell oncology sector, reflecting experts' confidence in the next generation of cell therapy.
Analysts' consensus forecast for the overall market share price
CERo Therapeutics is a biotech company developing next-generation cell therapy (CAR-T) that targets cancer cells. This chart reflects the overall market "risk appetite." For CERO, a high-risk clinical-stage company, overall market optimism (risk appetite) is critical to attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index CERo Therapeutics
CERo Therapeutics is a biotech R&D company focused on immuno-oncology. Their signature product is CER-T, a new type of cell therapy (TCR), which they claim is safer and more effective than CAR-T. This chart is a pure indicator of their faith in R&D. It doesn't reflect revenue, but rather a speculative assessment of their (very risky) pipeline and their clinical trial data.
AKIMA Market Segment Index - Oncology cell gene therapy
CERo Therapeutics (CERO) is developing a next-generation cell therapy (CER-T). Unlike standard CAR-T, their engineered cells are designed to recognize and attack multiple tumor targets simultaneously, which should aid in the treatment of solid tumors. This chart shows the average index for the segment, helping to assess how this complex technology compares to the average market.
The AKIM Index for the overall market
CERo Therapeutics is an immuno-oncology company developing a new class of cell therapy (CER T cells) that combines properties of innate and adaptive immunity. This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop important for funding this platform.
